Human metapneumovirus (HMPV) is a respiratory virus that causes mild to severe symptoms. It is one of the common viruses and is similar to Respiratory Syncytial Virus (RSV). However, the difference lies in the rate of hospital admissions for both. In case of Human metapneumovirus (HMPV) , hospitalization is common among infants between the ages of 6 and 12 months, and for Respiratory Syncytial Virus (RSV), hospitalization occurs between 2 and 3 months. Additionally, the clinical manifestations of both appear to be the same.
It belongs to the Pneumoviridae family of respiratory viruses. HMPV can affect people of all age groups; however, it most commonly impacts children, older adults, and individuals with weakened immune systems. HMPV is an enveloped virus with a negative-sense single-stranded RNA genome. It causes acute respiratory infections and is a significant contributor to both upper and lower respiratory tract illnesses and was first discovered in 2001 in the Netherlands. This virus infection usually can be managed at home, but determining when to seek medical attention is a critical question.
Human metapneumovirus is emerging as a major cause of respiratory disease, particularly among older adults and infants, causing illness in all age groups. Human Metapneumovirus (HMPV) is a respiratory system virus that can cause health issues from infancy through old age. It most commonly appears during the spring and winter seasons.
It is most commonly mild in healthy people. However, it is known to be fatal to infants, young children, the elderly, and immunocompromised persons. This blog discusses the symptoms of HMPV in Infants, Children, and Adults, the methods of diagnosis, available treatment options, the severity of the virus, and preventive measures. Additionally, the blog dive into the outbreaks reported in China and its global implication.
Human metapneumovirus, though generally a mild and common respiratory pathogen, can have significant effects on infants, older adults, and those with weakened immune systems. It often begins with cold-like symptoms but can progress to serious respiratory conditions such as pneumonia, leading to hospitalisation.
While it's not typically classified among the most severe viral infections, it can pose a considerable risk to individuals with underlying respiratory issues like asthma or Chronic Obstructive Pulmonary Disease (COPD), particularly in young children, where outcomes may be less favourable. In severe cases, the virus may advance to bronchitis or pneumonia, necessitating advanced medical intervention. In vulnerable groups such as older adults and children, closely monitoring the symptoms is crucial. When left untreated, it can lead to respiratory failure, often causing fatal complications for young children or the elderly.
Human metapneumovirus typically causes upper respiratory tract infections in children. Symptoms might include coughing, sneezing, nasal congestion, runny nose, fever, wheezing, fatigue, and, in severe cases, difficulty breathing. In some cases, it might also progress to more serious respiratory issues, such as bronchiolitis or pneumonia.
In healthy adult individuals, the symptoms of HMPV are usually mild and similar to those of a common cold, such as a runny nose, cough, mild fever, sore throat, and shortness of breath (in rare cases). The symptoms might be more severe and could escalate into complicated respiratory issues in immunocompromised individuals or those with pre-existing conditions like asthma or Chronic Obstructive Pulmonary Disease (COPD).
The diagnosis of Human metapneumovirus infection is based on clinical evaluative tests along with laboratory confirmation. Due to the similarity in symptoms with other respiratory viruses, especially Respiratory Syncytial Virus (RSV) and influenza, HMPV can be difficult to identify based on symptoms alone.
The diagnostic tests for detecting Human metapneumovirus are:
Polymerase Chain Reaction (PCR) test, which detects the presence of HMPV in respiratory samples such as nasal swabs.
Blood tests, which help identify signs of infection.
Chest X-ray can reveal pneumonia or other complications in severe cases.
These tests assist in confirming the diagnosis, guiding the treatment approach, and ruling out other similar respiratory viruses.
HMPV treatment typically involves over-the-counter medications, rest, and adequate hydration to help relieve symptoms like cough and fever. In more severe cases requiring hospitalisation, care may include corticosteroids, intravenous fluids, oxygen therapy, nebulised treatments, and other forms of respiratory support.
Most patients with Human metapneumovirus do not require hospitalization, although some cases may necessitate a short hospital stay. Factors such as marked respiratory distress, age under 2 years old, or older adults, underlying disease, and impaired immunity play a significant role in deciding the length of hospital admission.
The recovery time from Human metapneumovirus largely depends on the severity of the infection, as well as factors such as the person's age and overall health.
In mild cases, recovery typically occurs within one to two weeks with supportive care, including rest, hydration, and over-the-counter medications to relieve symptoms such as fever or chest congestion. In severe cases, recovery may take longer, particularly in patients with complications like pneumonia. Such cases could take weeks to recover, and some require hospital admission for full recovery. Supportive care, such as antivirals or oxygen therapy, may help those who have severe symptoms recover much faster.
In late 2024 and early 2025, China saw a large surge in respiratory illness and hospital admissions, particularly among children and the elderly. Patients have reported symptoms ranging from persistent cough and fever to more severe respiratory conditions such as bronchiolitis and pneumonia. HMPV’s similarity to other respiratory illnesses makes diagnosis and treatment more challenging. To control the spread of the virus, health authorities in China have promoted preventive measures such as handwashing, mask-wearing, and early testing.
The health authorities all over the world are well aware of the virus and are taking proper measures so that the virus is not widely spread, especially in winters and spring when the incidence of respiratory illness peaks.
Human metapneumovirus is transmitted via respiratory droplets released into the air when an infected individual coughs, sneezes, or speaks. It can also spread through direct contact with an infected person or touching the infected surfaces, such as door knobs or utensils. Furthermore, poorly ventilated or enclosed places are a risk factor for HMPV infection. Hence, the prevention of Human metapneumovirus primarily requires practicing good hygiene, as there is no vaccine available for HMPV. Therefore, the need for preventive measures takes priority.
The key preventive measures include:
Washing hands frequently
Avoid direct contact with individuals already suffering from HMPV infection.
Disinfect the surfaces and objects that come in direct contact with the infected person.
Stay in well-ventilated spaces.
Give special attention to high-risk groups, such as children and older adults, especially during the winter and spring seasons.
Wearing masks during outbreaks or flu season can help lessen the exposure to respiratory droplets in the air.
Isolate yourself when sick, as the virus can spread through the air or contaminated surfaces. Taking preventive steps is crucial to avoid passing the infection to others.
Human metapneumovirus (HMPV) is a virus that can affect all age groups of people, but children, elders, and immunocompromised individuals are at higher risk of becoming infected. However, there is no need to panic. It is important to stay informed about the virus, its symptoms, and when to seek medical attention. Maintaining proper hygiene and staying in well-ventilated places is the key to staying safe.
© Copyrights 2025 Medicoll All rights reserved.
